CCI
DNLI icon

Columbus Circle Investors’s Denali Therapeutics DNLI Stock Holding History

Columbus Circle Investors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$7.03M Buy
+83,949
New +$5.07M 0.31% 101

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Columbus Circle Investors's DNLI Position: Q4 2020 in Review

Columbus Circle Investors opened a new position in Denali Therapeutics (DNLI) in Q4 2020: 83,949 shares worth $7.03M. The stake represents 0.31% of the portfolio and ranks #101 among its holdings.

205 funds tracked by Wall St. Rank hold DNLI as of Q4 2020.

  • Columbus Circle Investors held 83,949 shares of Denali Therapeutics worth $7.03M as of Q4 2020.
  • Denali Therapeutics was a new Columbus Circle Investors position in Q4 2020.
  • Denali Therapeutics made up 0.31% of Columbus Circle Investors's portfolio in Q4 2020, its #101 holding.
  • 205 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2020.

Based on Columbus Circle Investors's 13F filing for Q4 2020, filed 20 Jan 2021.